22531-06-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Ethyl-1-tetralone serves as an intermediate in the synthesis of various pharmaceuticals and organic compounds. It plays a crucial role in the development of new drugs and the enhancement of existing ones, contributing to the advancement of medical treatments.
Used in Fragrance and Flavoring Industry:
7-Ethyl-1-tetralone is utilized in the production of fragrances and flavorings, capitalizing on its distinctive sweet, floral scent. It adds depth and complexity to perfumes and other aromatic products, as well as enriching the taste profiles of food and beverage items.
Environmental Considerations:
Given its classification as a potential environmental contaminant, the use and disposal of 7-Ethyl-1-tetralone are subject to regulatory measures. This ensures that its application in various industries is conducted responsibly, minimizing any adverse impact on the environment.

InChI:InChI=1/C12H14O/c1-2-9-6-7-10-4-3-5-12(13)11(10)8-9/h6-8H,2-5H2,1H3

Upstream product

• 7664-93-9 sulfuric acid 
• 5467-53-8 γ-(p-ethylphenyl)butyric acid 
• 49594-75-4 4-(4-ethylphenyl)-4-oxobutyric acid 
• 855221-60-2 4-(4-ethylphenyl)butanenitrile 
• 855215-98-4 4-(4-ethyl-phenyl)-butyryl chloride 

Downstream Products

• 13149-64-9 3-Hydroxy-2-<1-hydroxy-7-aethyl-naphthoyl-(2)>-benzoesaeure 
• 13243-90-8 6-Hydroxy-2-<1-hydroxy-7-aethyl-naphthoyl-(2)>-benzoesaeure 
• 13243-91-9 2-(4-Bromo-7-ethyl-1-hydroxy-naphthalene-2-carbonyl)-6-hydroxy-benzoic acid 
• 676133-21-4 (R)-7-ethyltetralin-1-ol 
• 146550-60-9 α,α-(7-ethyltetralin)-β-(p-methylbenzoyl) propionic acid 
• 146550-67-6 C₂₁H₂₁NO₂ 
• 146550-61-0 α,α-(7-ethyltetralin)-γ-(p-methylphenyl)butyric acid 
• 144404-63-7 ethyl α,α-(4-methyl-2-ketocyclohexane)-γ-(7'-ethyl-1'-naphthyl)butanoate 
• 108299-80-5 2-(7-ethyl-1-oxo-1,2,3,4-tetrahydro-[2]naphthyl)-propionic acid 
• 126309-61-3 (+/-)-α-anilino-deoxybenzoin-seqcis-oxime 
• 13112-58-8 7-ethyl-1-naphthol 
• 6333-77-3 7-ethyl-3,4-dihydro-2H-naphthalen-1-one semicarbazone 
• 22531-20-0 6-ethyltetralin 

Relevant academic research and scientific papers

Green synthesis method of medical intermediate benzocyclohexanone compound

The invention provides a green synthesis method of a benzocyclohexanone compound, and belongs to the technical field of organic synthesis. The method provided by the invention comprises the followingsteps: by taking 4-phenylbutyric acid as a raw material, firstly carrying out reflux reaction with oxalyl chloride in dichloromethane, carrying out vacuum evaporation to dryness to obtain a crude product of the 4-phenylbutyryl chloride compound, then dissolving the crude product in a solvent, adding a metal-doped modified molecular sieve catalyst to start reaction, and stirring the solution at different temperatures to carry out ring closing reaction, thereby obtaining the product; and after the reaction is finished, carrying out suction filtration, solvent washing, column chromatography purification and other operations to obtain the target product benzocyclohexanone compound. The synthesis method disclosed by the invention is environment-friendly in reaction and simple and convenient tooperate, the catalyst can be recycled, and the synthesis method is suitable for green synthesis of the benzocyclohexanone compound.

PYRAZOLE-CONTAINING MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS

In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating inflammatory disease, neurological disorders and cancer using the compounds of the invention.

Optimization of Pyrazoles as Phenol Surrogates to Yield Potent Inhibitors of Macrophage Migration Inhibitory Factor

Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that is implicated in the regulation of inflammation, cell proliferation, and neurological disorders. MIF is also an enzyme that functions as a keto–enol tautomerase. Most potent MIF tautomerase inhibitors incorporate a phenol, which hydrogen bonds to Asn97 in the active site. Starting from a 113-μm docking hit, we report results of structure-based and computer-aided design that have provided substituted pyrazoles as phenol alternatives with potencies of 60–70 nm. Crystal structures of complexes of MIF with the pyrazoles highlight the contributions of hydrogen bonding with Lys32 and Asn97, and aryl–aryl interactions with Tyr36, Tyr95, and Phe113 to the binding.

4,5-DIHYDRONAPHTHO [1,2-b] THIOPHENE DERIVATIVE

A 4,5-dihydronaphtho[1,2-b]thiophene derivative expressed by the formula: (wherein R1 is a C1 to C10 1-hydroxyalkyl group or a C1 to C10 acyl group, and R2 and R3 separately substitute in the 6-, 7-, 8-, or 9-positions, and are each independently a hydrogen atom, a halogen atom, a C1 to C10 alkyl group, a hydroxy group, a C1 to C10 alkoxy group, a C1 to C5 alkenyloxy group, a C1 to C5 alkynyloxy group, a benzyloxy group, or the like, provided that when R1 is an acyl group and R2 is a hydrogen atom, then R3 is neither a hydrogen atom nor an acetyl group), or a pharmaceutically acceptable salt thereof. This is a novel compound that is effective in reducing triglyceride levels in the liver and reducing blood glucose levels.

ARYL(ALKYL)PROPYLAMIDES

The invention relates to a compound selected from those of formula (I) : STR1 in which A, R 1, R' 1, R 2, R 3 and n are as defined in the description, and medicinal product containing the same useful for treating a mammal afflicted with a disorder of the

TETRAHYDRO-1H-BENZAZEPINONES AND HEXAHYDROAZEPINONES AS SELECTIVE CHOLECYSTOKININ-B RECEPTOR ANTAGONISTS

This invention relates to compounds of formula (I) wherein R. sup.1, R. sup.2, R 3, R 4 and X are as defined in the application. These compounds are CCK-B receptor antagonists and are useful in the treatment and prevention of central nervous system and gastrointestinal disorders. STR1

Synthesis of Substituted Chrysenes

Syntheses of 3-ethyl-9-methylchrysene (9) and 1,3,9-trimethylchrysene (9a) are described. 2-(7'-Ethyl-1'-naphthyl)ethyl bromide (6) and 2-(5',7'-dimethyl-1'-naphthyl)ethyl bromide (6a) were condensed separately with 2-carbethoxy-5-methylcyclohexanone to afford ethyl α,α-(4-methyl-2-cyclohexanone)-γ-(7'-ethyl-1'-naphthyl)butyrate (7) and ethyl α,α-(4-methyl-2-cyclohexanone)-γ-(5',7'-dimethyl-1'-naphthyl)butyrate (7a) respectively.PPA cyclisation of 7 gave a mixture of 8 and 8b while that of 7a gave only 8a.Catalytic dehydrogenation of 8 and 8b afforded 9 and that of 8a gave 9a.The products were characterised by physical data.